Scancell Holdings PLC (GB:SCLP)
LSE:SCLP
SCLP Stock Chart & Stats
9.75 p
0.40 p(4.06%)
At close: 4:00 PM EST
9.75 p
0.40 p(4.06%)
Day’s Range― - ―
52-Week Range7.80 p - 14.00 p
Previous CloseN/A
Volume797.06K
Average Volume (3M)1.20M
Market Cap
£116.75M
Enterprise Value124.36M
Total Cash (Recent Filing)£8.57M
Total Debt (Recent Filing)£16.18M
Price to Earnings (P/E)―
Beta0.21
Next Earnings
Oct 23, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding1,037,781,400
10 Day Avg. Volume991,653
30 Day Avg. Volume1,200,950
Financial Highlights & Ratios
PEG Ratio-0.10
Price to Book (P/B)-27.20
Price to Sales (P/S)22.14
P/FCF Ratio-17.04
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.01
Revenue Forecast (FY)£833.33K
Bulls Say, Bears Say
Bulls Say
Regulatory / Registrational PathwayIND clearance and FDA acceptance of the dose, design and a surrogate primary endpoint materially reduce regulatory uncertainty. This creates a credible, accelerated registrational pathway, improving partner and investor confidence and making financing and strategic alliances more attainable over the medium term.
Strong Phase II Efficacy Signal & BiomarkerA compelling Phase II PFS signal increases the probability the asset can show meaningful clinical benefit in Phase III. The identified biomarker to enrich responders further reduces development risk and increases the chance of a positive registrational outcome and commercial differentiation if replicated.
Manufacturing & Delivery ScalabilityHaving scalable manufacturing and an established delivery partner addresses common commercialization bottlenecks. These capabilities lower time-to-market and per-dose risk, support regulatory filings, and make the program more attractive to partners, reducing execution risk after approval.
Bears Say
Balance Sheet WeaknessNegative equity and material debt constrain financial flexibility and weaken solvency optics. This reduces negotiating leverage with partners and lenders, increases refinancing risk, and makes the company more reliant on external funding or milestone receipts to execute an expensive Phase III program.
Near-Term Cash Runway & Financing RiskA runway into H2 2026 forces near-term capital decisions that can drive dilution or onerous partnership terms. Funding uncertainty can delay trials, constrain operational flexibility, and create execution risk for the planned Phase III unless non-dilutive milestones materialize or a favorable financing/partnering deal is secured.
Long Development Timeline & Clinical UncertaintyA multi-year blinded Phase III delays definitive value realization and revenue generation, increasing cumulative funding needs and exposure to clinical risk. Cross-study Phase II comparisons have limitations, so the positive signal must be confirmed; prolonged timelines can also damp partner appetite and strategic optionality.
Scancell Holdings News
SCLP FAQ
What was Scancell Holdings PLC’s price range in the past 12 months?
Scancell Holdings PLC lowest share price was 7.80 p and its highest was 14.00 p in the past 12 months.
What is Scancell Holdings PLC’s market cap?
Scancell Holdings PLC’s market cap is £116.75M.
When is Scancell Holdings PLC’s upcoming earnings report date?
Scancell Holdings PLC’s upcoming earnings report date is Oct 23, 2026 which is in 203 days.
How were Scancell Holdings PLC’s earnings last quarter?
Scancell Holdings PLC released its earnings results on Jan 29, 2026. The company reported -0.006 p earnings per share for the quarter, missing the consensus estimate of N/A by -0.006 p.
Is Scancell Holdings PLC overvalued?
According to Wall Street analysts Scancell Holdings PLC’s price is currently Overvalued.
Does Scancell Holdings PLC pay dividends?
Scancell Holdings PLC does not currently pay dividends.
What is Scancell Holdings PLC’s EPS estimate?
Scancell Holdings PLC’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Scancell Holdings PLC have?
Scancell Holdings PLC has 1,037,781,400 shares outstanding.
What happened to Scancell Holdings PLC’s price movement after its last earnings report?
Scancell Holdings PLC reported an EPS of -0.006 p in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -2.804%.
Which hedge fund is a major shareholder of Scancell Holdings PLC?
Currently, no hedge funds are holding shares in GB:SCLP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Scancell Holdings Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
-29.25%
12-Months-Change
Fundamentals
Return on Equity
90.29%
Trailing 12-Months
Asset Growth
-7.40%
Trailing 12-Months
Company Description
Scancell Holdings PLC
Scancell Holdings plc, a clinical stage biopharmaceutical company, engages in the discovery and development of novel vaccines and antibody medicines to treat unmet needs in cancer and infectious diseases. The company's product candidates include SCIB1, which is in phase II clinical trial for the treatment of metastatic melanoma; SCIB2 for the treatment of non-small cell lung cancer; and Modi-1 that is in phase I/II clinical trials for the treatment of head and neck, triple negative breast, ovarian, and renal cancers. It also develops Modi-2, which targets homocitrullinated cancer antigens. In addition, the company develops SCOV1 and SCOV2 COVIDITY, a prophylactic DNA vaccine against the SARS-CoV-2 virus. Scancell Holdings plc was founded in 1997 and is based in Oxford, the United Kingdom.
Technical Analysis
Sareum Holdings
―
4basebio UK Societas
―
Poolbeg Pharma Ltd.
―
Arecor Therapeutics PLC
―
Ondine Biomedical, Inc.
―
Options Prices
Currently, No data available
---